{"entity":{"id":"nct07406633","kind":"trial","name":"KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)","aka":[],"tldr":"A phase 2 trial of Imatinib in metastatic cancer, run by Kumquat Biosciences Inc., now recruiting.","summary":"KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line) is a phase 2 interventional study registered as NCT07406633 by Kumquat Biosciences Inc., with 46 participants planned, started 2026-06-23 and due to reach its primary completion in 2027-10. Interventions recorded: KQB198, Imatinib (Gleevec). Conditions listed: GIST - Gastrointestinal Stromal Tumor, GIST, GIST Metastatic Cancer, Gastro Intestinal Stromal Tumour. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07406633","url":"https://clinicaltrials.gov/study/NCT07406633"}],"tags":["ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["imatinib"],"companies":["kumquat-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07406633","phase":"2","setting":"A Phase 2, Multicenter, Study Evaluating the Efficacy, Safety, Tolerability, Pharmacokinetics of KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GI Stromal Tumor in 1st Line Setting","sponsor":"Kumquat Biosciences Inc.","participation":[{"nct":"NCT07406633","source":"https://clinicaltrials.gov/study/NCT07406633","fetchedAt":"2026-10-07T16:55:43.582Z","studySha256":"eed9f16ebaf2721b6c360b06c6a8c5dfc6109ca7dd642853721591eeafd63f19","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-10","leadSponsor":"Kumquat Biosciences Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":46,"enrolmentType":"ESTIMATED","siteCount":17,"recruitingSiteCount":17,"countries":["United States"]}],"started":"2026-06-23","startedType":"actual","enrolled":46,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07406633/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/"}],"company":[{"id":"kumquat-biosciences","kind":"company","name":"Kumquat Biosciences","route":"/companies/kumquat-biosciences/"}]}}